Entera Bio (NASDAQ:ENTX) Stock Bumped Down to Strong Sell by Wall Street Zen

Wall Street Zen downgraded shares of Entera Bio (NASDAQ:ENTX) from a sell rating to a strong sell rating in a research note released on Saturday morning,Wall Street Zen reports.

ENTX has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, October 15th. Guggenheim assumed coverage on Entera Bio in a report on Thursday, September 24th. They issued a “buy” rating and a $11.00 price objective for the company. Lifesci Capital began coverage on Entera Bio in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price objective on the stock. UBS Group set a $9.00 price objective on Entera Bio in a research report on Friday, September 18th. Finally, Cantor Fitzgerald assumed coverage on Entera Bio in a report on Tuesday, September 22nd. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Entera Bio presently has an average rating of “Moderate Buy” and an average target price of $9.60.

Entera Bio Price Performance

Shares of ENTX opened at $3.14 on Friday. The firm’s 50 day simple moving average is $2.88 and its 200 day simple moving average is $1.95. The company has a market capitalization of $546.12 million, a P/E ratio of -8.05 and a beta of 1.48. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20.

Entera Bio (NASDAQ:ENTX) last announced its earnings results on Friday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). On average, equities analysts anticipate that Entera Bio will post -0.40 earnings per share for the current year.

Institutional Trading of Entera Bio

An institutional investor recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP increased its stake in Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 205,542 shares of the company’s stock after acquiring an additional 70,224 shares during the period. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 as of its most recent SEC filing. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.